The devices recently gained the regulatory greenlight, and both medical devicemakers are about to enter a market that includes more than 100 million people.
Margaret Kaczor Andrew, an analyst at William Blair, told the Post there are about 7.5 million diabetic patients in the U.S. who use insulin, meaning there are roughly 25 million diabetic patients who might benefit from continuous glucose monitors. Another 100 million people who are prediabetic might also jump at the new OTC device.
Neither company has disclosed the list prices, and most insurance plans are unlikely to cover the cost, according to the Post.
Dexcom said its product will launch in late August, and Abbott said it is planning its device to debut this summer.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
